Drug Trial Radar · NCT01601704
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
Last checked: Nov 19, 2026Latest source record: Feb 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8,910
Actual
Start
Jun 2012
Primary completion
Aug 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Orexigen Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.
Conditions
- Obesity
- Overweight
Interventions
NB32Drug
Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
PBODrug
Placebo. Administered in addition to the weight management program.
Weight Management ProgramBehavioral
A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)Time frame: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
Locations
224 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Dothan, Alabama
Site not named
Mobile, Alabama
Site not named
Scottsboro, Alabama
Site not named
Chandler, Arizona
Site not named
Mesa, Arizona
Site not named
Peoria, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Tuscson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Carmichael, California
Site not named
Escondido, California
Site not named
Fresno, California
Site not named
Harbor City, California
Site not named
Huntington Beach, California
Site not named
La Jolla, California
Site not named
Lomita, California
Site not named
Los Angeles, California
Site not named
Paramount, California
Site not named
Pasadena, California
Site not named
Riverside, California
Site not named
Sacramento, California
Site not named
Santa Rosa, California
Site not named
Spring Valley, California
Site not named
Thousand Oaks, California
Site not named
Torrance, California
Site not named
West Hills, California
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Site not named
Golden, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Norwalk, Connecticut
Site not named
Stamford, Connecticut
Site not named
Wilmington, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Boynton Beach, Florida
Site not named
Brooksville, Florida
Showing 40 of 224 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.